West Pharmaceutical Services Inc. (WST)
NYSE: WSTHealth CareMedical/Dental InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
WST stock chart
Technical analysisKey statistics
All statistics- Market cap
- $27.19B
- P/E (TTM)
- 43.80
- Forward P/E
- 37.55
- EPS (TTM)
- $8.91
- Dividend yield
- 0.23% ($0.88)
- Ex-dividend date
- Jul 29, 2026
- 52-week range
- 223.83 – 438.27
- Day range
- 389.75 – 400.90
- Volume / Avg
- 623.34K / 619.05K
- Beta
- —
- Shares outstanding
- 69.66M
52-week range
WST stock today
West Pharmaceutical Services (WST) closed at $390.30 on Nov 20, down 1.61% (-$6.39), versus the S&P 500's 3.70% decline. At this level, WST sits in the middle of its 52-week range of $223.83 to $438.27: 10.9% below the high, set on Oct 29, 2026 and 74.4% above the low. WST is up 41.9% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 44.0%.
At 43.8x trailing earnings, West Pharmaceutical Services trades above the peer-group median of 26.5x. Its forward P/E of 37.6x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. West Pharmaceutical Services pays an annual dividend of $0.88 per share, a 0.23% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About West Pharmaceutical Services
Company profileWest Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. Michel Lagarde
- Headquarters
- Exton, PA
- Employees
- 10,000
- Website
- westpharma.com
Financial highlights
Full financialsIn fiscal 2025, West Pharmaceutical Services generated $3.07 billion in revenue, up 6.3% from fiscal 2024. Net income was $493.7 million (+0.2% year over year), for a net margin of 16.1% versus a median of 20.1% in the prior 5 years. Gross margin was 35.9% (up from 34.5%) and operating margin 19.0%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $3.07B | $2.89B | $2.95B | $2.89B | $2.83B |
| Growth | +6.25% | -1.92% | +2.18% | +1.95% | +31.89% |
| Net income | $493.70M | $492.70M | $593.40M | $585.90M | $661.80M |
| EPS (diluted) | $6.79 | $6.69 | $7.88 | $7.73 | $8.67 |
Analyst forecast
ForecastConsensus (16 analysts)
strong_buy
Avg. price target
$471.00+20.68%
- Strong buy 3
- Buy 12
- Hold 0
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 29, 2026
- EPS actual vs est.
- $1.96 vs $2.18
- Surprise
- -10.09%
Dividends
Dividend history- Annual dividend
- $0.88
- Dividend yield
- 0.23%
- Last payment
- $0.22
- Ex-dividend date
- Jul 29, 2026
WST news
All WST news- Here's Why You Should Retain Ecolab Stock in Your Portfolio NowNasdaqECL, ISRG, WST, GKOS
- GEHC Advances Manganese-Based MRI Agent to Phase 3 After Positive DataNasdaqGEHC, ISRG, WST, GKOS
- Hims & Hers Launches Peptides+ to Expand Personalized Health CareNasdaqHIMS, ISRG, WST, GKOS
- GE HealthCare Wins FDA Nod for AI Feeding Tube Detection SoftwareNasdaqGEHC, ISRG, WST, GKOS
- Here's Why You Should Retain NeuroPace Stock in Your Portfolio for NowNasdaqNPCE, ISRG, WST, GKOS
- Philips Unveils Skylight Device Manager to Boost Ultrasound EfficiencyNasdaqPHG, ISRG, WST, GKOS
- Reasons to Add West Pharmaceutical Stock to Your Portfolio NowNasdaqWST, ISRG, CAH, GKOS
- Here's Why You Should Retain OPK Stock in Your Portfolio for NowNasdaqOPK, ISRG, WST, GKOS
West Pharmaceutical Services peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| DXCMDexCom Inc. | 79.32 | -1.08% | $29.58B | vs WST |
| RMDResMed Inc. | 235.63 | -0.53% | $33.14B | vs WST |
| SOLVSolventum Corporation | 84.50 | -1.52% | $14.36B | vs WST |
| GKOSGlaukos Corporation | 237.31 | -0.33% | $14.05B | vs WST |
| BAXBaxter International Inc. | 25.39 | 0.00% | $13.14B | vs WST |
| PENPenumbra Inc. | 319.12 | -0.28% | $12.58B | vs WST |
| PODDInsulet Corporation | 133.17 | -2.96% | $9.24B | vs WST |
| GMEDGlobus Medical Inc. Class A | 66.89 | -2.49% | $8.86B | vs WST |
Indexes, lists and sector
West Pharmaceutical Services stock FAQ
What is West Pharmaceutical Services's stock price today?
WST last traded at $390.30 as of Nov 20, 4:00 PM EST, down 1.61% on the day. Prices are delayed at least 15 minutes.
Does West Pharmaceutical Services pay a dividend?
Yes. West Pharmaceutical Services pays $0.88 per share annually, a 0.23% yield. The most recent dividend of $0.22 had an ex-dividend date of Jul 29, 2026.
What is WST's P/E ratio?
WST trades at a trailing P/E ratio of 43.80 and a forward P/E of 37.55, compared with a median of 26.5 for its closest peers.
Is West Pharmaceutical Services in the S&P 500?
Yes. West Pharmaceutical Services (WST) is a constituent of the S&P 500 index.
Who is West Pharmaceutical Services's CEO?
Mr. Michel Lagarde is the chief executive officer of West Pharmaceutical Services Inc., which has about 10,000 employees.
Has WST ever split its stock?
Yes. The most recent WST stock split was a 2-for-1 split on Sep 27, 2013, one of 4 splits on record.
What is the WST 52-week high?
The 52-week high for WST is $438.27 and the 52-week low is $223.83. The stock is currently 10.9% below its high.